Treating mucormycosis using a multimodality approach: a case series

Abstract Background Treatment of aggressive pituitary adenomas typically involves a multimodality approach based on histopathological features and may include pharmacotherapy, surgery, and occasionally radiation therapy. In cases of treatment-refractory tumor progression, chemotherapy may be considered; however, no standard chemotherapeutic regimen has been established. Literature review suggests that temozolomide may have a beneficial role in a subset of cases. To understand the efficacy of temozolomide in progressive pituitary tumors, we reviewed the outcomes of cases at our center. Methods We performed a retrospective chart review to report the outcome and unique features of 7 patients with aggressive functioning pituitary adenomas or carcinomas treated with temozolomide. Tumor pathology included somatotroph (n = 1), corticotroph (n = 3), and lactotroph (n = 3) tumors. Results Four of the 7 patients had at least 2 prior resections, and all had prior radiation and surgery before treatment with temozolomide. Notably, all patients showed response to therapy, defined as either stable disease (43%) or partial response (57%). Median progression-free survival was 1.66 years, and median overall survival was 4 years. Conclusion Our data suggest that temozolomide has an important role in the management of aggressive functioning pituitary tumors that are resistant to standard therapies, and that optimization of therapy with temozolomide may involve individualized regimens. Future prospective clinical trials should be considered.

Download Full-text

Do Primitive Neuroectodermal Tumors of the Kidney Have a Predilection for Inferior Vena Cava Involvement? A Case Series and Review of the Literature

Journal of Kidney Cancer and VHL ◽

10.15586/jkcvhl.2020.153 ◽

2020 ◽

Vol 7 (4) ◽

pp. 8-16

Author(s):

Sovan Hota ◽

Sidhartha Kalra ◽

Lalgudi Narayanan Dorairajan ◽

Ramanitharan Manikandan ◽

Sreerag Kodakkattil Sreenivasan

Keyword(s):

Inferior Vena Cava ◽

Renal Pelvis ◽

Inferior Vena ◽

Vena Cava ◽

Case Series ◽

Rare Presentation ◽

Friend Leukemia ◽

Renal Pnet ◽

Multimodality Approach ◽

Cluster Of Differentiation

The primitive neuroectodermal tumor (PNET) of the kidney is an extremely rare neoplasm, the diagnosis of which mainly depends upon histopathology, immunohistochemistry (IHC), and cytogenetics. A handful of cases reported in the literature mention about aggressive features of this neoplasm. The purpose of our study was to review our experience in not only the diagnosis and management of the patients with renal PNET but also to highlight its propensity to involve inferior vena cava (IVC) and also present a rare occurrence of Ewing’s sarcoma (ES)/PNET of the renal pelvis. The clinical, operative, and histopathology records of four patients of renal PNET treated between January 2017 and December 2019 were reviewed and data analyzed concerning the available literature. Out of the four patients treated, two had level III and IV IVC thrombus, and one had dense desmoplastic adhesions with the IVC wall. One of the cases had a rare presentation of ES/PNET of the renal pelvis. All patients were managed surgically, while only one patient received adjuvant chemotherapy and following up with remission for the last 2 years and 4 months. On IHC, cluster of differentiation-99 (CD-99) was positive in all patients, and three were positive for Friend leukemia integration-1. PNET of the kidney is primarily an immunohistopathological diagnosis. This neoplasm has an increased propensity for the local invasion of surrounding structures. A multimodality approach with surgery, chemotherapy, and radiotherapy could offer better outcomes, although the prognosis of these tumors remains poor.

Download Full-text

A multi-centre case series investigating the aetiology of hypertrophic pachymeningitis with orbital inflammation

Yearbook of Ophthalmology ◽

10.1016/j.yoph.2012.05.025 ◽

2012 ◽

Vol 2012 ◽

pp. 219-220

Author(s):

K. Talekar ◽

A. Flanders

Keyword(s):

Case Series ◽

Hypertrophic Pachymeningitis ◽

Orbital Inflammation

Download Full-text

Abstract #726: Primary Hyperparathyroidism and the Relationship Between 25-Vitamin D, 1,25 Vitamin D and Parathyroid Hormone: A Prospective Case Series

Endocrine Practice ◽

10.1016/s1530-891x(20)42709-0 ◽

2015 ◽

Vol 21 ◽

pp. 137-138

Author(s):

Thomas Hadwen ◽

Melissa Clarke ◽

Ashim Sinha

Keyword(s):

Vitamin D ◽

Parathyroid Hormone ◽

Primary Hyperparathyroidism ◽

Case Series ◽

Prospective Case Series ◽

The Relationship

Download Full-text

Abstract #856 A Case Series Review of Clinical and Biochemical Characteristics of Pituitary Abcess in Mexican Patients

Endocrine Practice ◽

10.1016/s1530-891x(20)47342-2 ◽

2018 ◽

Vol 24 ◽

pp. 202-203

Author(s):

Mireya Perez-Guzman ◽

Alfredo Nava de la Vega ◽

Arturo Pena Velarde ◽

Tania Raisha Torres Victoria ◽

Froylan Martinez-Sanchez ◽

...

Keyword(s):

Case Series ◽

Biochemical Characteristics ◽

Mexican Patients

Download Full-text

Abstract #316: Latent Auto-Immune Diabetes in Adults (LADA): Is it More Prevalent Than We Think? A Case Series

Endocrine Practice ◽

10.1016/s1530-891x(20)45024-4 ◽

2016 ◽

Vol 22 ◽

pp. 95

Author(s):

Chandni Merchant ◽

Smita Kargutkar

Keyword(s):

Case Series

Download Full-text

Cannabis-associated arteritis

VASA ◽

10.1024/0301-1526/a000004 ◽

2010 ◽

Vol 39 (1) ◽

pp. 43-53 ◽

Cited By ~ 17

Author(s):

Grotenhermen

Keyword(s):

Systematic Review ◽

Case Reports ◽

Case Series ◽

Cardiovascular Effects ◽

Causative Factor ◽

Cannabis Use ◽

Thromboangiitis Obliterans ◽

Pathological Features ◽

Scientific Support ◽

Clinical And Pathological Features

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term cannabis arteritis should be avoided until or unless more convincing scientific support is forthcoming.

Download Full-text